This week has seen the launch of new and lower-priced biosimilars to AbbVie’s Humira (adalimumab), many months after Amgen’s Amjevita (adalimumab-atto) was released in the
The EMA's human medicines committee has recommended approval of Roche's Ronapreve and Celltrion's Regkirona for use in COVID-19, the first antibody-based therapies for coronavirus to be bac
The EU looks set to approve emergency use of a third antibody therapy for COVID-19 after its human medicines committee backed use of Celltrion's regdanvimab at its March meeting. <
South Korea’s Celltrion has announced encouraging top-line results for its potential antibody therapy for COVID-19, with the first part of a phase 2/3 trial showing it could cut recovery ti
South Korea’s Celltrion has made its first major acquisition, buying a portfolio of drugs including diabetes and hypertension drugs from Takeda that will expand its expertise with small mol
It has been five years since Lexicon Pharma's type 1 diabetes therapy, Zynquista, was rejected by the FDA, and it may struggle to have a better outcome at its second attempt.